Daniel B. Soland's most recent trade in Acadia Pharmaceuticals Inc was a trade of 13,793 Director Stock Options (Right to Buy) done . Disclosure was reported to the exchange on May 29, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Acadia Pharmaceuticals Inc | Daniel B. Soland | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 May 2025 | 13,793 | 13,793 | - | - | Director Stock Options (Right to Buy) | |
| Acadia Pharmaceuticals Inc | Daniel B. Soland | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 29 May 2025 | 9,387 | 0 | - | - | Restricted Stock Units | |
| Acadia Pharmaceuticals Inc | Daniel B. Soland | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 29 May 2025 | 9,387 | 44,041 (0%) | 0% | - | Common Stock | |
| Acadia Pharmaceuticals Inc | Daniel B. Soland | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 May 2025 | 8,107 | 8,107 | - | - | Restricted Stock Units | |
| Acadia Pharmaceuticals Inc | Daniel B. Soland | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 May 2024 | 15,959 | 15,959 | - | - | Director Stock Options (Right to Buy) | |
| Acadia Pharmaceuticals Inc | Daniel B. Soland | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 May 2024 | 9,387 | 9,387 | - | - | Restricted Stock Units | |
| Acadia Pharmaceuticals Inc | Daniel B. Soland | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 29 May 2024 | 6,652 | 34,654 (0%) | 0% | - | Common Stock | |
| Acadia Pharmaceuticals Inc | Daniel B. Soland | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 29 May 2024 | 6,652 | 0 | - | - | Restricted Stock Units | |
| Acadia Pharmaceuticals Inc | Daniel B. Soland | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jun 2022 | 14,368 | 14,368 | - | - | Director Stock Options (Right to Buy) | |
| Acadia Pharmaceuticals Inc | Daniel B. Soland | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jun 2022 | 8,552 | 8,552 | - | - | Restricted Stock Units | |
| KalVista Pharmaceuticals Inc | Daniel B. Soland | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Sep 2021 | 10,000 | 10,000 | - | - | Director Stock Option (Right to Buy) | |
| Acadia Pharmaceuticals Inc | Daniel B. Soland | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Jun 2021 | 11,637 | 11,637 | - | - | Director Stock Options (Right to Buy) | |
| Acadia Pharmaceuticals Inc | Daniel B. Soland | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Jun 2021 | 11,045 | 11,045 | - | - | Director Stock Options (Right to Buy) | |
| Acadia Pharmaceuticals Inc | Daniel B. Soland | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 Jun 2021 | 8,552 | 28,002 (0%) | 0% | - | Common Stock | |
| Acadia Pharmaceuticals Inc | Daniel B. Soland | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 Jun 2021 | 8,552 | 0 | - | - | Restricted Stock Units | |
| Acadia Pharmaceuticals Inc | Daniel B. Soland | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Jun 2021 | 6,652 | 6,652 | - | - | Restricted Stock Units | |
| Acadia Pharmaceuticals Inc | Daniel B. Soland | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Jun 2021 | 6,391 | 6,391 | - | - | Restricted Stock Units | |
| Acadia Pharmaceuticals Inc | Daniel B. Soland | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 Jun 2021 | 6,391 | 19,450 (0%) | 0% | - | Common Stock | |
| Acadia Pharmaceuticals Inc | Daniel B. Soland | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 Jun 2021 | 6,391 | 0 | - | - | Restricted Stock Units | |
| Acadia Pharmaceuticals Inc | Daniel B. Soland | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 Jun 2021 | 3,059 | 13,059 (0%) | 0% | - | Common Stock | |
| Acadia Pharmaceuticals Inc | Daniel B. Soland | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 Jun 2021 | 3,059 | 0 | - | - | Restricted Stock Units | |
| KalVista Pharmaceuticals Inc | Daniel B. Soland | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Oct 2020 | 7,000 | 7,000 | - | - | Director Stock Option (right to buy) | |
| KalVista Pharmaceuticals Inc | Daniel B. Soland | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Oct 2020 | 7,000 | 7,000 | - | - | Director Stock Option (right to buy) |